Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.
CSP #428 - Treatment of Seizures in the Elderly Population
Sponsor: Glaxo Wellcome
Listed as NCT00007670, this PHASE3 trial focuses on Seizures and remains completed. Sponsored by Glaxo Wellcome, it has been updated 8 times since 1998, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Nov 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jan 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Glaxo Wellcome
- Parke-Davis
- US Department of Veterans Affairs
For direct contact, visit the study record on ClinicalTrials.gov .